Long-term safety and efficacy of picotamide, a dual-action antithromboxane agent, in diabetic patients with carotid atherosclerosis: A 6-year follow-up study

Journal of International Medical Research

Volumn 26, Issue 4, 1998, Pages 200-205

  Coto, V ^a   Oliviero, U ^a   Cocozza, M ^a   Milani, M ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Italy   (Italy)

Author keywords

Diabetics; Picotamide; Platelet aggregation; Thromboxane antagonists; Vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; PICOTAMIDE; TICLOPIDINE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; STROKE; THROMBOCYTE AGGREGATION; VASCULAR DISEASE;

EID: 7844223995     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059802600404     Document Type: Article

References (18)

1. Yudkin J: Coronary heart disease in diabetes mellitus: three new risk factors and unifying hypothesis. J Intern Med 1995; 238: 21-30.
2. Stamler Y, Vaccaro O, Neaton J, et al: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
3. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy part 1. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
4. Cimminiello C, Milani M: Diabetes mellitus and peripheral vascular disease: is aspirin effective in preventing vascular events? Diabetologia 1996; 39: 1402-1404.
5. Colwell J, Bingham S, Abraira C, et al: Veterans' Administration cooperative study group on antiplatelet agents in diabetic patients after amputation for gangrene. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care 1986; 9: 140-148.
6. Marwick C: Aspirin's role in prevention now official. JAMA 1997; 277: 701-702.
7. Duggan J, Dobson A, Johnson H: Peptic ulcer and non-steroidal anti-inflammatory agents. Gut 1986; 27: 929-933.
8. 2 receptor antagonist. Br J Pharmacol 1994; 112: 81-86.
9. Milani M, Longoni A, Maderna M: Effects of Picotamide, an antiplatelet agent, on cardiovascular events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. Br J Clin Pharmacol 1996; 42: 782-785.
10. Balsano F, Violo F, the ADEP Group: Effects of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. Circulation 1993; 87: 1563-1569.
11. 2 receptor antagonist, reduces exercise-induced albuminuria in microalbuminuric patients with NIDDM. Diabetes 1993; 42: 178-182.
12. Desenzani P, Perini P, Milani M, et al: Long-term picotamide, a dual thromboxane inhibitor decreases both the urinary excretion of thromboxane B, an albumin in patients with type 2 diabetes. Diabetes 1997; 40:(Suppl 1): 2148.
13. Cocozza M, Picano T, Oliviero U, et al: Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution. Stroke 1995; 26: 597-601.
14. Schneider D, Sobel B: Determinants of coronary vascular disease in patients with type II diabetes mellitus and their therapeutic implications. Clin Cardiol 1997; 20: 433-440.
15. Lundberg V, Stegmayr B, Asplund K, et al: Diabetes as a risk factor for myocardial infarction: population and gender perspectives. J Intern Med 1997; 241: 485-492.
16. Davì G, Gresele P, Violi F, et al: Diabetes mellitus, hypercholesterolemia and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Circulation 1997; 96: 69-75.
17. Cotè R, Battista R. Abrahamowicz M, et al: Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. Ann Intern Med 1995; 123: 649-655.
18. Violi F, Longoni A, Maderna M, et al: Safety of picotamide, an antiplatelet agent, in an 18-month, double-blind, placebo-controlled, multicentor trial in 2304 patients with peripheral vascular disease. Curr Ther Res 1993; 54: 111-121.